Clinical evaluation of Xiao'er Xiaoji Zhike Oral Liquid in the treatment of severe community-acquired pneumonia in children
LIU Jing
LYU Ming
Abstract：Objective To explore the clinical efficacy of Xiao'er Xiaoji Zhike Oral Liquid as an adjunct to individ-ualized anti-infection regimens in children with severe community-acquired pneumonia(SCAP).Methods A prospective con-trolled study design was adopted.A total of 100 children with SCAP treated at Baoji Maternal and Child Health Hospital from April 2023 to March 2025 were selected and randomly assigned into two groups using a computer-generated random number sequence(50 cases each).Two cases in the control group discontinued treatment and one was lost to follow-up,while three cases in the observation group were lost to follow-up.Ultimately,both groups comprised 47 cases each.The control group received an individualized basic treatment regimen based on pathogen types,and the observation group additionally received Xiao'er Xiaoji Zhike Oral Liquid.The clinical efficacy,recovery time of respiratory symptoms,Traditional Chinese Medicine(TCM)syndrome scores,levels of inflammatory factors and incidence of adverse reactions were compared between the two groups before and af-ter treatment.Results After 7 days of treatment,the total effective rate in observation group was 95.74%(45/47),higher than that in the control group(78.72%(37/47))(χ2=6.114,P=0.013).The recovery times for fever,cough and expectoration,and pul-monary rales in the observation group((2.24±1.21),(3.77±0.98),(4.61±1.12)days,respectively)were shorter than those in the control group((3.37±1.81),(4.32±1.33),and(5.24±1.03)days,respectively)(t=3.558,2.282,2.838,all P<0.05).TCM syndrome scores for fever,wheezing,cough frequency,abdominal distension,fatigue and dizziness in the observation group((1.31±0.35),(1.36±0.29),(1.29±0.38),(0.66±0.23),(0.73±0.27),(0.69±0.25)points,respectively)were lower than those in the control group((2.45±0.37),(2.56±0.31),(2.48±0.38),(1.47±0.28),(1.37±0.24),(1.35±0.21)points,respectively)(t=15.345,19.380,15.181,15.325,12.146,13.858,all P<0.05).The proportion of neutrophils,the levels of serum interleukin-6 and C-reactive protein in the observation group((45.68±8.45)%,(53.12±1.31)pg/L,(13.03±1.98)mg/L,respectively)were lower than those in the control group((49.65±9.28)%,(55.21±1.19)pg/L,(16.89±2.01)mg/L,respectively)(t=2.169,8.096,9.379,all P<0.05).The incidence of adverse reactions was 12.77%(6/47)in the observation group and 17.02%(8/47)in the control group,with no statistically significant difference(χ2=0.336,P=0.562).Conclusion Xiao'er Xiaoji Zhike Oral Liquid as an adjunct to individualized an-ti-infection therapy can alleviate the clinical symptoms in children with SCAP,accelerate the recovery of respiratory function,reduce systemic inflammatory response,and exhibit a favorable safety profile.
Keywords：community acquired pneumoniaXiao'er Xiaoji Zhike Oral Liquidclinical efficacyinflammatory factors
Publication Date：2026-02-25
Online Publishing Date：2026-03-16(First online date of this platform, not the publication date of the document)
Pages：5( 272-276 )